Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset

NCT05700591 is registered in ClinicalTrials.gov with Tasly Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT05700591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05700591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset
Lead sponsor
Tasly Biopharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
January 29, 2023
Completion date
March 14, 2024
Enrollment
1,552 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke